Skip to main content
Syros partners with Incyte on rare bone marrow disorder drug studies

Syros Pharmaceuticals and Incyte agreed to work together on the development of potential drugs to treat patients with myeloproliferative neoplasms. Under the terms of the deal, Syros will receive $20 million upfront and Incyte will have the option to obtain exclusive rights for therapies modulating up to seven validated targets discovered during the collaboration.

Full Story: